Selected Grants
A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies
Clinical TrialPrincipal Investigator · Awarded by Arcus Biosciences · 2022 - 2027DEK-DKK1-P205
Clinical TrialPrincipal Investigator · Awarded by Leap Therapeutics, Inc. · 2020 - 2025Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings
ResearchCo Investigator · Awarded by National Institutes of Health · 2023 - 2025An mHealth Symptom Management Intervention for Colorectal Cancer Patients
ResearchCo Investigator · Awarded by American Cancer Society, Inc. · 2021 - 2024Couple Communication Skills Training for Advanced Cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2020 - 2024A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies
Clinical TrialPrincipal Investigator · Awarded by Arcus Biosciences · 2022 - 2027DEK-DKK1-P205
Clinical TrialPrincipal Investigator · Awarded by Leap Therapeutics, Inc. · 2020 - 2025Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings
ResearchCo Investigator · Awarded by National Institutes of Health · 2023 - 2025An mHealth Symptom Management Intervention for Colorectal Cancer Patients
ResearchCo Investigator · Awarded by American Cancer Society, Inc. · 2021 - 2024Couple Communication Skills Training for Advanced Cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2020 - 2024A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo asFirst-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Juncti
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2018 - 2024Key-LARGO: A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients with Gastro-esophageal Cancer,"
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2017 - 2024A Randomized multicenter double blind Phase III study of Nivolumab or placebo in subjects with resected esophageal junction cancer.
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2016 - 2024A Phase 1b/2 open label dose escalation study of Margetuximab incombination with Pembrolizumab in patients with relapsed refrectory advanced HER2 + Gastroesophageal junction or gastric cancer.
Clinical TrialPrincipal Investigator · Awarded by MacroGenics, Inc. · 2016 - 2021Multiple Co-occurring Symptoms in Patients with Gastrointestinal Cancers
FellowshipSponsor · Awarded by American Cancer Society, Inc. · 2020 - 2021A Multicenter randomized open label study in patients with esophageal cancer refractory or intorlerant to combination therapy with fluoropyrimidine
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2016 - 2021LYC-55716-1001
Clinical TrialPrincipal Investigator · Awarded by Lycera Corporation · 2017 - 2020A Phase 2 study of ADXS11-001 i subjects with persistent/recurrent loco-regional or metastatic squamous cell carcinoma of the anorectal canal.
Clinical TrialPrincipal Investigator · Awarded by Advaxis Inc · 2015 - 2019External Relationships
- Arcus
- Astellas Pharma Inc.
- AstraZeneca
- Bristol-Myers Squibb
- Leap Therapeutics
- Arcus
- Astellas Pharma Inc.
- AstraZeneca
- Bristol-Myers Squibb
- Leap Therapeutics
- Macrogenics, Inc.
- Merck
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.